Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive

Posts in: perriman

Damien Perriman interviewed for Springwise
press clippingsperrimanNCT
Springwise case study: Unpacking how eXoZymes and Cayman Chemical are rethinking chemical manufacturingApril 17, 2026
Grow Everything podcast featuring Damien Perriman
press releasenutraceuticalsmedicinepress clippingsvideosciencepodcastperrimanNCT
eXoZymes CCO, Damien Perriman, outlines NCTx strategy and the commercial path for cell-free biomanufacturing on Grow Everything podcastApril 10, 2026
Perriman at Nasdaq
investornutraceuticalsmedicinepress clippingsvideoperrimanNCT
Nasdaq: Damien Perriman interview on NCTApril 2, 2026
eXoZymes de-risks scale-up with Cayman Chemical, validating tech transfer with pharma-grade output
investornutraceuticalsmedicineperrimanNCT
EXOZ investor update: eXoZymes de-risks scale-up with Cayman Chemical, validating tech transfer with pharma-grade outputMarch 18, 2026
Video interview: Cayman Chemical validates eXoZymes' technology and scalability
press releasenutraceuticalsmedicinevideoperrimanNCT
Video interview: Successful pilot scale run with Cayman Chemical validates eXoZymes' technology and scalabilityMarch 18, 2026
2026 MISTA Symposium Healthspan
press releasenutraceuticalsmedicineperrimanNCT
eXoZymes’ CCO Damien Perriman to Present a NCT solution at next week’s MISTA SymposiumMarch 12, 2026
Vanity Fair: Inside NCTx - How A Rare Plant-Derived Molecule Is Turning Fat Into A Boost Of Energy
nutraceuticalsmedicinepress clippingsperrimanNCT
Vanity Fair: Inside NCTx - How A Rare Plant-Derived Molecule Is Turning Fat Into A Boost Of EnergyNovember 26, 2025

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark